Biomea Fusion, Inc. (BMEA)

32.35 +1.64 (+5.34%) At close: 04:00PM EDT

Biomea Fusion, Inc.

900 Middlefield Road
4th Floor
Redwood City, CA 94063
United States
650 980 9099
https://biomeafusion.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 75

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Thomas Andrew Butler	Co-Founder, Chairman & CEO	772.86k	N/A	1981
Mr. Ramses M. Erdtmann	Co-Founder, Pres, COO & Director	570.57k	N/A	1963
Mr. Franco Valle	CFO & Principal Accounting Officer	251.69k	N/A	1981
Mr. Heow Tan	Chief Technology & Quality Officer	N/A	N/A	1959
Ms. Naomi Cretcher	Chief People Officer	N/A	N/A	N/A
Dr. Thorsten Kirschberg Ph.D.	Exec. VP of Chemistry	N/A	N/A	1970
Dr. Stephan Morris M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. Ravi Upasani	Sr. VP of Intellectual Property	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Corporate governance

Biomea Fusion, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.